News

The trial will investigate the use of Ovasave, an antigen-specific regulatory T (Ag-Treg) autologous cell-based immunotherapy for the treatment of patients with moderate to severe refractory Crohn’s disease.

Neptune may appeal this decision, but cannot submit any additional evidence or claim amendments. Enzymotec president and CEO Dr Ariel Katz noted that this final decision by the

Foamix now has a total of 25 issued US Patents, 61 issued worldwide and 126 patents pending. These new patents, which were issued between August 2013 and January

The approval makes CYRAMZA, the first FDA-approved treatment for patients with metastatic gastric cancer. Lilly Oncology senior vice president of product development and medical affairs Richard Gaynor said

CFFT is the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation. This agreement allows Alcresta to accelerate the development of its nutrition technology and advance

Pursuant to the terms of the research collaboration agreement, NanoSmart Pharmaceuticals and NanoValent Pharmaceuticals will explore the feasibility of jointly developing an anti-nuclear antibody (ANA)-conjugated liposomal doxorubicin nanoparticle

The featured article describes the outcome in 52 advanced cancer patients treated with Xilonix, XBiotech’s novel, non-cytotoxic, anti-tumor therapy. The so called true human antibody therapy was reported

Volasertib is an investigational compound that inhibits enzymes called Polo-like kinase. Currently, the drug is being assessed in a Phase III clinical trial for the treatment of patients

MultiCorp International CEO Paul D. Lisenby noted that the company is extremely excited to have such a qualified and experienced group to assist the company in mapping out